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integrated miRnA-/mRnA-Seq 
of the Habenulo-interpeduncular 
circuit During Acute nicotine 
Withdrawal
Alison p. casserly1,2, Junko tsuji  3, Rubing Zhao-Shea1, Ciearra B. Smith1,4, Susanna Molas1, 
Andrew R. tapper  1, Zhiping Weng  3 & paul D. Gardner1*
Tobacco use is the leading preventable cause of mortality in the world. The limited number of smoking 
cessation aids currently available are minimally effective, highlighting the need for novel therapeutic 
interventions. We describe a genome-wide approach to identify potential candidates for such 
interventions. next-generation sequencing was performed using RnA isolated from the habenulo-
interpeduncular circuit of male mice withdrawn from chronic nicotine treatment. this circuit plays 
a central role in the nicotine withdrawal response. Differentially expressed miRNAs and mRNAs 
were validated using RT-qPCR. Many of the differentially expressed mRNAs are predicted targets 
of reciprocally expressed miRnAs. We illustrate the utility of the dataset by demonstrating that 
knockdown in the interpeduncular nucleus of a differentially expressed mRNA, that encoding profilin 
2, is sufficient to induce anxiety-related behavior. Importantly, profilin 2 knockdown in the ventral 
tegmental area did not affect anxiety behavior. Our data reveal wide-spread changes in gene expression 
within the habenulo-interpeduncular circuit during nicotine withdrawal. this dataset should prove to 
be a valuable resource leading to the identification of substrates for the design of innovative smoking 
cessation aids.
Tobacco use is a prevalent health problem worldwide, with more than 900 million daily smokers1 and an esti-
mated 6 million deaths due to tobacco-related illnesses annually2. The few pharmacological cessation aids cur-
rently available have limited efficacy3–6. Without the intervention of new effective treatments, tobacco-related 
mortality is anticipated to rise to 8 million deaths per year2.
The addictive component of tobacco is nicotine, an agonist of nicotinic acetylcholine receptors (nAChRs), 
ligand-gated ion channels endogenously activated by acetylcholine7. nAChRs are enriched in the mesolimbic 
and habenulo-interpeduncular circuitries involved in nicotine reward and withdrawal, respectively8–10. Cessation 
of nicotine induces a withdrawal syndrome consisting of negative somatic, affective and cognitive symptoms. 
Affective symptoms include depressed mood, irritability, craving and anxiety11,12. While the rewarding properties 
of nicotine dominate initial drug-taking, it is largely avoidance of affective withdrawal symptoms that promotes 
relapse and habitual use13,14.
The habenulo-interpeduncular circuitry consists primarily of neurons projecting from the medial habenulae 
(MHb) to the interpeduncular nucleus (IPN) via the fasciculus retroflexus. In mice experiencing spontaneous 
nicotine withdrawal, there is increased glutamate release from habenular axon terminals, activating GABAergic 
neurons in the IPN15. Activation of the IPN results in the increased somatic signs and anxiety observed during 
nicotine withdrawal15,16. Optogenetic investigation of this circuit has revealed that silencing the MHb decreases 
activation of IPN neurons and decreases anxiety during nicotine withdrawal16.
While much is known about the neurocircuitry responsible for nicotine withdrawal-associated behaviors, 
the mechanisms underlying the induction of these behavioral alterations are less clear. Chronic drug exposure 
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induces stable neuroadaptations underlying the compulsion for continued use and susceptibility to relapse. These 
long-lasting changes in the function of the addicted brain are thought to require alterations of gene expression 
through regulation of transcription factors, epigenetic mechanisms and non-coding RNAs17,18.
microRNAs (miRNAs) are non-coding RNA molecules ~22 nucleotides in length that repress the expres-
sion of mRNA targets by promoting mRNA decay or translational repression19. miRNAs recognize their targets 
through imperfect base-pairing of the seed region (nucleotides 2–7) with miRNA response elements (MREs) 
within the 3′-untranslated regions (UTRs) of mRNAs20,21. Tobacco smoke and nicotine have been shown to reg-
ulate the expression of miRNAs in various cell lines, organisms and tissues22–26.
Dysregulation of miRNAs in the brain have been shown to contribute to neurodevelopmental and neuropsy-
chiatric disorders, including drug addiction27,28. However, little is known about the role of miRNAs in the mech-
anisms underlying nicotine dependence and withdrawal. Few studies have examined the regulation of miRNAs 
by nicotine in specific regions of the mammalian brain29–31. Previously, we showed that the expression of miRNAs 
predicted to target MREs within the 3′-UTRs of nAChR genes was altered after chronic nicotine treatment in 
whole brain or a specific brain region30. Nicotine has been reported to regulate miRNAs and mRNAs in the MHb, 
with microarrays detecting expression changes in mice self-administering nicotine31. However, the targets of 
these miRNAs and their functions in the context of nicotine dependence have not been elucidated.
Using integrated miRNA- and mRNA-Seq, we asked whether there are changes in miRNA and mRNA expres-
sion in the MHb and IPN during acute nicotine withdrawal. We hypothesize that using these sequencing datasets 
as valuable resources, it will be possible to identify a multitude of miRNAs/genes playing a role(s) in the mecha-
nisms underlying the neuroadaptations involved in nicotine dependence.
Results
Differential expression of miRNAs and mRNAs in the habenulo-interpeduncular axis during 
acute withdrawal from nicotine. To assess the regulation of miRNAs and mRNAs by chronic nicotine 
treatment (Nic) and acute withdrawal (NAWD), we sequenced and performed differential expression analysis of 
RNAs isolated from the IPN and MHb (Fig. 1B–M; Figs. S2 and S3). As a reference brain region outside of the 
habenulo-interpeduncular circuit, we sequenced RNA from the nucleus accumbens (NAc), a prominent mes-
olimbic reward region (Fig. 1N–S; Figs. S2 and S3).
In the habenulo-interpeduncular circuit, there were few miRNAs differentially expressed after chronic nico-
tine treatment. In the IPN, only 8 miRNAs were significantly altered after nicotine treatment alone (Fig. 1B). The 
7 down-regulated miRNAs remained similarly repressed after a 48-hr withdrawal (see GEO upload). In the MHb, 
there were only 6 differentially expressed miRNAs in Nic mice compared to TA controls (Fig. 1H), and only 1 
remained similarly regulated after nicotine was discontinued (see GEO upload).
However, after acute nicotine withdrawal, the expression of a multitude of miRNAs was altered in the 
habenulo-interpeduncular circuit. In the IPN of NAWD mice, there were 42 up-regulated and 45 down-regulated 
miRNAs in NAWD mice compared to TA controls (Fig. 1C). Twenty-nine of these miRNAs were similarly differ-
entially expressed when NAWD mice are compared to either TA or Nic mice (Fig. 1D), suggesting their regulation 
in the IPN is due entirely to withdrawal and not an effect of nicotine exposure alone.
In the MHb, there were 35 up-regulated and 50 down-regulated miRNAs in NAWD mice compared to TA 
controls (Fig. 1I). Forty miRNAs were similarly differentially expressed when NAWD mice are compared to either 
TA or Nic (Fig. 1J), suggesting their expression was altered only after withdrawal, and was not simply an effect of 
the nicotine treatment.
To determine the persistence of the alterations in miRNA expression following acute nicotine withdrawal, 
another group of mice underwent a long (4-week) withdrawal after chronic nicotine treatment (NLWD) prior 
to sequencing. Interestingly, there were no differentially expressed miRNAs in either the IPN or MHb of NLWD 
mice compared to age-matched TA-treated (TAL) controls (Fig. S2S–V).
In the NAc, expression of 12 miRNAs was altered in Nic mice (Fig. 1N). However, in NAWD mice only 2 
miRNAs were differentially expressed (Fig. 1O). Twenty-six miRNAs were differentially expressed in NLWD 
mice compared to TAL controls (Fig. S2W,X), and none of these were similarly altered in acute withdrawal (see 
GEO upload).
With respect to the mRNAs, few were regulated by chronic nicotine treatment with a fold change >2 in 
the IPN and MHb. In the IPN, there were 4 differentially expressed mRNAs in Nic mice compared to controls 
(Fig. 1E) and all of these returned to control expression levels in NAWD mice (see GEO upload). In the MHb, 
there were 18 mRNAs up- and 8 mRNAs down-regulated by chronic nicotine treatment compared to TA controls 
(Fig. 1K) and only 2 remained differentially expressed after acute withdrawal (see GEO upload).
In contrast to chronic nicotine treatment alone, there were 292 up- and 43 down-regulated mRNAs in the IPN 
of NAWD mice compared to TA controls (Fig. 1F). Of these mRNAs, 303 were similarly altered when NAWD 
mice are compared to either TA or Nic mice (Fig. 1G), suggesting their regulation was an effect of acute nicotine 
withdrawal and not an effect of nicotine treatment alone.
In the MHb, there were 151 up- and 3 down-regulated mRNAs in NAWD mice compared to TA controls 
(Fig. 1L). When NAWD mice were compared to either TA or Nic, the expression of 122 mRNAs was similarly 
altered (Fig. 1M), suggesting their regulation was an effect of acute withdrawal from nicotine and not an effect of 
nicotine treatment alone.
In the NAc, in contrast to the habenulo-interpeduncular circuit, there were a total of 852 genes differentially 
expressed in Nic compared to TA mice (Fig. 1Q). After acute withdrawal, there were only 31 mRNAs differen-
tially expressed in the NAc of NAWD mice compared to TA (Fig. 1R). Of these mRNAs, 25 were also altered after 
nicotine-treatment alone, suggesting this was largely an effect of the chronic nicotine treatment (Fig. 1S).
To determine the stability of altered mRNA expression induced by nicotine withdrawal, NLWD mice were 
compared to TAL controls. In the IPN, 39 genes were differentially expressed in NLWD mice compared to TAL 
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Figure 1. Differential expression of miRNAs and mRNAs within the MHb-IPN withdrawal axis and NAc 
during acute nicotine withdrawal. (A) Schematic of nicotine treatment and spontaneous withdrawal of mice 
used for miRNA- and mRNA-Seq. Mice were treated chronically with nicotine (Nic) or tartaric acid (TA) for 6 
weeks, then either sacrificed or spontaneously withdrawn (WD) for 48 hours before sacrifice (NAWD). (B–S) 
Scatter plots displaying differential expression of miRNAs or mRNAs in the IPN, MHb, and NAc measured by 
deep sequencing. miRNAs isolated from tissue punches of nicotine-treated (B,H,N) and NAWD-treated mice 
are compared to TA-treated controls (C,I,O) or nicotine alone samples (D,J,P). mRNAs of nicotine-treated 
(E,K,Q) and NAWD-treated mice are compared to TA-treated controls (F,L,R) or nicotine alone samples 
(G,M,S). Each dot represents an individual miRNA or mRNA plotted as log2(RPM) or log2(TPM), respectively. 
All miRNAs with an FDR < 0.01 and mRNAs with FDR < 0.01 and FC > 2 are highlighted in color. Orange 
dots are up-regulated in TA compared to Nic or NAWD. Green dots are up-regulated in Nic compared to 
TA controls. Red dots are up-regulated in NAWD compared to TA controls. Only miRNAs with RPM > 0 
and mRNAs with TPM > 0 in at least half of the replicates in each treatment group are shown. n = 4–5, with 
each library synthesized using pooled RNA from 4 mice. (T–V) Genes differentially expressed during acute 
nicotine withdrawal are enriched in gene ontology terms related to energetics, translation, and cell projection 
organization in the IPN and MHb. The vertical axes define the selected GO terms describing the cellular 
compartment (T), molecular function (U), or biological process (V). The number of GO terms was reduced 
combining similar terms using a simRel cutoff of 0.4 as described in the Materials and Methods. The horizontal 
axis plots the significance of enrichment of the GO term, plotted as −log10(FDR).
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(Fig. S3S,T). However, none of these genes were differentially expressed after acute withdrawal (see GEO upload). 
In the MHb, all mRNAs were expressed at control levels in NLWD mice (Fig. S3U,V).
Gene ontology analysis was performed on differentially expressed mRNAs for all treatment groups and brain 
regions (Fig. 1T–V, Table S1). For genes up- or down-regulated in the IPN and MHb of NAWD mice compared 
to TA controls, we determined enrichment of reduced terms describing the cellular compartment (CC, Fig. 1T), 
molecular function (MF, Fig. 1U), and biological process (BP, Fig. 1V). CC analysis determined there was signifi-
cant enrichment of genes up-regulated in the IPN related to the mitochondrion. There was also enrichment of MF 
and BP terms related to mitochondrion, such as electron carrier activity, NADH dehydrogenase activity, hydrogen 
ion transport, and regulation of metabolic processes. There was also significant enrichment of genes up-regulated 
in the IPN related to ribosomal terms, including structural constituent of the ribosome, rRNA binding, ribosome 
biogenesis, and translation. In both the IPN and the MHb there was significant enrichment of down-regulated 
genes related to neuron projection development.
Differentially expressed miRNAs are predicted to target reciprocally expressed mRNAs in the 
ipn and MHb during acute nicotine withdrawal. TargetScan Mouse 7.1 was used to identify transcripts 
containing conserved MREs potentially targeted by miRNAs in all treatment groups and brain regions (Table S2).
In the IPN, 38 mRNAs that were differentially expressed in NAWD mice compared to controls are predicted 
targets of at least one of 35 inversely expressed miRNAs (Table 1). For example, expression of Profilin 2 (Pfn2), 
a regulator of cytoskeletal dynamics enriched in the brain32, was down-regulated by ~50% in the IPN of NAWD 
mice. miR-106b-5p is up-regulated by ~80% and is predicted to target two MREs within the 3′-UTR of Pfn2.
In the MHb, 50 mRNAs that were differentially expressed in NAWD mice compared to TA controls are 
predicted targets of at least one of 32 inversely expressed miRNAs (Table 2). The up-regulation of at least four 
mRNAs (Arf5, Atg7, Bcl2l1, and Eif5a) that are predicted to be targeted by down-regulated miRNAs (Table 2), was 
verified by RT-qPCR (Fig. S4D–G).
In the NAc, neither of the miRNAs differentially expressed in NAWD mice compared to TA-treated controls 
are conserved, and therefore were not considered in target analysis. However, after nicotine treatment alone, there 
were 204 differentially expressed mRNAs predicted to be targeted by at least one of 8 inversely expressed miRNAs 
(Table S2).
Down-regulation of Pfn2 in the IPN is sufficient to induce anxiety. Withdrawal from nicotine 
induces anxiety in mice through activation of the IPN16. Using our treatment paradigm, NAWD mice display 
increased anxiety compared to nicotine- and TA-treated controls, as measured by the marble burying test and 
EPM (Fig. S4A–C). Because Pfn2-/- mice display increased synaptic vesicle exocytosis and hyperactivation of 
neurons33, we hypothesized that repression of Pfn2 in the IPN is sufficient to induce anxiety, mimicking the 
behaviors observed in NAWD mice. To knockdown Pfn2 expression, three different lentiviral shRNAs were tested 
in SN17 cells, revealing that lenti-pGIPZ-Pfn2-shRNA494369-tGFP produced robust knockdown (~81%) com-
pared to virus expressing a scramble control shRNA (Fig. S5A). Injection of the IPN with lenti-pGIPZ-Pfn2-shRN
A494369-tGFP (Fig. 2A) resulted in ~54% knockdown of Pfn2 expression in areas expressing tGFP compared to 
animals injected with control virus (Fig. 2B). Virus expression was limited to the IPN and adjacent brain areas, 
with no spread to distant midbrain regions, as detected by fluorescence microscopy (Fig. S5B). Quite strikingly, 
when Pfn2 was knocked down in the IPN, mice spent significantly less time in the open arms of the EPM com-
pared to controls (Fig. 2C). Importantly, there was no significant difference in the number of total arm entries, 
indicating the results are not confounded by non-specific effects on locomotor activity (Fig. 2C). However, when 
Pfn2 was knocked down in the neighboring VTA (Fig. 2D), there was no significant effect on the amount of 
time spent in the open arms of the EPM or total arm entries (Fig. 2E). Because the IPN is also a prominent brain 
region in the circuitry underlying novelty preference34 and novelty seeking behaviors are altered in Pfn2 knockout 
mice33, we also tested the effect of Pfn2 knockdown on object novelty preference. Expression of lenti-pGIPZ-Pfn
2-shRNA494369-tGFP in the IPN did not significantly affect the time spent exploring familiar and novel objects 
or the novel object preference ratio compared controls (Fig. S6).
Discussion
Using RNA sequencing and differential expression analysis, we identified wide-spread changes in both miRNA 
and mRNA expression in the MHb-IPN withdrawal circuit during acute nicotine withdrawal. In contrast, 
there were a limited number of miRNAs/mRNAs altered by acute nicotine withdrawal in the NAc, a prominent 
reward center, suggesting that wide-spread changes in transcription during acute withdrawal occur in a brain 
region-specific manner, concentrated in the habenulo-interpeduncular circuitry.
In the MHb and IPN, miRNAs and mRNAs that were altered during acute nicotine withdrawal largely 
returned to control expression levels after a prolonged withdrawal. This is most striking in the MHb where there 
were no differentially expressed miRNAs or mRNAs 4 weeks after withdrawal. In the IPN, none of the mRNAs 
differentially expressed after a long withdrawal were similarly altered at the 48-hour withdrawal time point. This 
suggests that for a subset of genes in the IPN, changes in mRNA expression induced by nicotine withdrawal 
occur over a longer timescale and persist for at least 4 weeks. This subpopulation of genes stably dysregulated by 
nicotine treatment and withdrawal may contribute to the persistent susceptibility to relapse that plagues nicotine 
addicts.
Gene ontology analysis identified significant enrichment of up-regulated genes in the IPN related to ribosome 
structure and translation, further supporting the body of evidence suggesting that stable neuroadaptations asso-
ciated with drug addiction require de novo protein synthesis17. Thus, it is possible that up-regulation of ribosomes 
and other regulators of translation fulfills the increased demand for protein products in the IPN during nicotine 
withdrawal. In addition, in the MHb and IPN, there is significant enrichment of up-regulated genes related to 
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mRNA mRNA FC mRNA FDR miRNA miRNA FC miRNA FDR Seed Type Position in 3′-UTR
Hbq1a 3.002 2.57E-07 miR-377-3p 0.592 1.08E-03 7mer-m8 252–258
Rpp21 2.852 2.35E-20 miR-136-5p 0.613 9.18E-06 8mer 3537–3544
Gchfr 2.696 9.55E-06
miR-129-1-3p 0.570 4.18E-04 7mer-m8 298–304
miR-129-2-3p 0.590 1.62E-05 7mer-m8 298–304
Gm20390 2.669 2.25E-23
miR-429-3p 0.329 3.53E-12 7mer-m8 3377–3383
miR-429-3p 0.329 3.53E-12 8mer 4329–4336
miR-429-3p 0.329 3.53E-12 8mer 4714–4721
miR-200b-3p 0.375 6.58E-08 7mer-m8 3377–3383
miR-200b-3p 0.375 6.58E-08 8mer 4329–4336
miR-200b-3p 0.375 6.58E-08 8mer 4714–4721
miR-344d-3p 0.741 4.47E-03 7mer-A1 3316–3122
Gm9726 2.627 2.76E-04 miR-29b-3p 0.726 4.41E-03 8mer 326–333
Hist1h4h 2.505 1.18E-15 miR-9-5p 0.753 5.60E-03 7mer-m8 26–32
Serf2 2.421 7.81E-20
miR-200a-3p 0.381 1.24E-13 7mer-m8 213–219
miR-141-3p 0.458 3.07E-04 7mer-m8 213–219
let-7f-5p 0.735 8.04E-04 8mer 2110–2117
let-7b-5p 0.741 6.40E-03 8mer 2110–2117
let-7c-5p 0.766 9.52E-03 8mer 2110–2117
Mrps16 2.418 2.40E-15 miR-136-5p 0.613 9.18E-06 7mer-m8 86–92
Zfp46 2.409 3.91E-12
miR-129-1-3p 0.570 4.18E-04 7mer-m8 464–470
miR-129-2-3p 0.590 1.62E-05 7mer-m8 464–470
Ndufb2 2.368 2.31E-22
miR-429-3p 0.329 3.53E-12 7mer-m8 3896–3902
miR-200b-3p 0.375 6.58E-08 7mer-m8 3896–3902
Esrrb 2.332 7.67E-08
let-7f-5p 0.735 8.04E-04 8mer 617–624
let-7b-5p 0.741 6.40E-03 8mer 617–624
miR-485-5p 0.753 4.04E-03 7mer-m8 55–61
miR-9-5p 0.753 5.60E-03 8mer 2337–2344
let-7c-5p 0.766 9.52E-03 8mer 617–624
Polr2f 2.323 2.02E-26 miR-488-3p 0.752 8.56E-03 7mer-m8 485–491
Nme1 2.305 3.32E-21
miR-200a-3p 0.381 1.24E-13 8mer 123–130
miR-141-3p 0.458 3.07E-04 8mer 123–130
Gm9844 2.296 1.27E-04 miR-129-5p 0.721 1.46E-03 8mer 26–33
Diras1 2.234 1.93E-12 miR-7b-5p 0.715 1.25E-03 7mer-m8 2200–2206
Myl6 2.234 8.56E-15 miR-340-5p 0.741 6.55E-03 7mer-A1 851–857
Psma2 2.174 3.46E-21 miR-132-3p 0.726 6.55E-03 7mer-A1 111–117
Mrpl14 2.172 2.53E-14 miR-340-5p 0.741 6.55E-03 7mer-A1 2823–2829
Ptrhd1 2.170 1.90E-13
miR-181d-5p 0.676 2.00E-04 7mer-m8 2022–2028
miR-181b-5p 0.680 5.42E-05 7mer-m8 2022–2028
miR-488-3p 0.752 8.56E-03 8mer 76–83
Dynlt1f 2.169 1.11E-08 miR-29b-3p 0.726 4.41E-03 7mer-A1 215–221
Sod1 2.162 7.65E-13 miR-377-3p 0.592 1.08E-03 7mer-m8 78–84
Cst6 2.158 6.60E-14
miR-377-3p 0.592 1.08E-03 7mer-m8 2027–2033
miR-181d-5p 0.676 2.00E-04 7mer-m8 2023–2029
miR-181b-5p 0.680 5.42E-05 7mer-m8 2023–2029
Rpl31 2.153 6.45E-09
miR-653-5p 0.616 4.04E-03 7mer-A1 639–645
miR-129-5p 0.721 1.46E-03 8mer 671–678
Tmsb4x 2.126 2.94E-14 miR-183-5p 0.319 3.96E-21 7mer-m8 327–333
Ndufb9 2.104 7.81E-20
miR-200a-3p 0.381 1.24E-13 8mer 2453–2460
miR-141-3p 0.458 3.07E-04 8mer 2453–2460
miR-365-3p 0.654 9.94E-03 7mer-m8 2718–2724
miR-532-5p 0.740 2.06E-03 7mer-m8 3048–3054
miR-340-5p 0.741 6.55E-03 7mer-A1 1850–1856
miR-379-5p 0.752 6.55E-03 7mer-m8 3186–3192
Rps12 2.097 2.19E-06 miR-96-5p 0.235 1.36E-17 7mer-m8 2285–2291
Continued
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the mitochondria. The functions of activated neurons, including maintenance of membrane resting potential, 
intracellular calcium buffering, and synaptic vesicle recycling, are highly energy-demanding35,36. To meet the 
increased demand, neurons increase oxidative metabolism, but cannot up-regulate glycolysis37. The enrichment 
of up-regulated genes related to mitochondria and oxidative energy production reflect the highly active synapses 
of the IPN during nicotine withdrawal.
An interesting outcome of our work is the realization that some of the miRNAs we demonstrated to be differ-
entially expressed as a result of nicotine withdrawal have been shown by others to regulate expression of mRNAs 
encoding cholinergic transcripts. Such miRNAs are referred to as CholinomiRs38 and include, for example, miR-
132 that targets acetylcholinesterase39,40, as well as miR-211 that targets the gene encoding the alpha7 subunit of 
nAChRs41. Given that CholinomiRs function in a combinatorial manner such that their impact is a consequence 
of interactions between competing miRNAs and targets38, our dataset should prove useful in further elucidating 
the mechanisms underlying changes in cholinergic signaling that occur due to nicotine withdrawal.
As an example of the utility of our RNA-Seq data, we focused upon one example of a gene differentially 
regulated during acute nicotine withdrawal in the IPN. Pfn2 is a member of the profilin family of small, actin 
monomer-binding proteins42,43. While Pfn1 is ubiquitously expressed throughout the body, Pfn2 expression is 
highest in the brain32 and represents approximately 75% of the profilin in rodent brain32,44. In addition to its 
ability to bind actin monomers, Pfn2 has a poly-l-proline binding domain allowing it to interact with a pleth-
ora of ligands whose functions contribute to synaptic morphology and function42. Pfn2 is expressed pre- and 
post-synaptically33. Pre-synaptically, Pfn2 can influence synaptic vesicle release through interaction with regula-
tors of membrane trafficking and endocytosis45,46. Interestingly, Pfn2 −/− mice display higher vesicle exocytosis 
and hyperactivation of the striatum33. Post-synaptically, Pfn2 accumulates in dendritic spines of activated neu-
rons47,48, and plays a role in determining their complexity through the regulation of cytoskeletal dynamics49,50. 
Pfn2 regulates actin polymerization at the synapse by direct interaction with the WAVE-complex33, which in turn 
activates the Arp2/3 complex to promote actin nucleation. Interestingly, Arpc3 is a confirmed target of miR-29a/b, 
which is up-regulated in the mouse brain after acute nicotine injection, regulating dendritic spine morphology29. 
Furthermore, Pfn2 interacts directly with ROCK, a RhoA-GTPase effector, regulating neuritogenesis in response 
mRNA mRNA FC mRNA FDR miRNA miRNA FC miRNA FDR Seed Type Position in 3′-UTR
Acot13 2.097 2.94E-07
miR-429-3p 0.329 3.53E-12 7mer-m8 4417–423
miR-200b-3p 0.375 6.58E-08 7mer-m8 4417–423
miR-653-5p 0.616 4.04E-03 7mer-A1 5139–5145
miR-181d-5p 0.676 2.00E-04 7mer-m8 4525–4531
miR-181b-5p 0.680 5.42E-05 7mer-m8 4525–4532
Aamdc 2.094 9.88E-15 miR-485-5p 0.753 4.04E-03 7mer-m8 64–70
Cisd3 2.093 9.98E-20 miR-9-5p 0.753 5.60E-03 7mer-A1 358–364
Tmem151b 2.035 2.86E-07
miR-129-1-3p 0.570 4.18E-04 7mer-m8 2722–2728
miR-129-2-3p 0.590 1.62E-05 7mer-m8 2722–2728
miR-181d-5p 0.676 2.00E-04 7mer-m8 2226–2232
miR-181b-5p 0.680 5.42E-05 7mer-m8 2226–2233
miR-132-3p 0.726 6.55E-03 8mer 339–346
miR-29b-3p 0.726 4.41E-03 7mer-m8 2452–2458
miR-485-5p 0.753 4.04E-03 8mer 2089–2096
Erh 2.031 1.69E-09
miR-181d-5p 0.676 2.00E-04 7mer-m8 118–124
miR-181b-5p 0.680 5.42E-05 7mer-m8 118–124
Tomm5 2.011 4.37E-19 miR-151-3p 0.770 6.36E-03 7mer-m8 383–389
Gosr2 0.374 1.22E-11 miR-27a-3p 1.421 8.66E-04 8mer 94–101
Nkx2-1 0.459 1.19E-03 miR-503-5p 1.581 1.48E-03 7mer-m8 74–80
Prkag1 0.488 8.60E-03
miR-34a-5p 1.941 7.79E-08 7mer-m8 42–48
miR-34b-5p 1.893 1.43E-06 7mer-m8 42–48
Lurap1l 0.489 1.18E-06
miR-497a-5p 2.053 3.09E-13 8mer 60–67
miR-503-5p 1.581 1.48E-03 7mer-A1 61–67
Pfn2 0.496 8.36E-09
miR-106b-5p 1.789 9.32E-11 7mer-m8 452–458
miR-106b-5p 1.789 9.32E-11 7mer-m8 1197–1203
Zbtb9 0.496 3.34E-05
miR-497a-5p 2.053 3.09E-13 7mer-m8 42–48
miR-497a-5p 2.053 3.09E-13 7mer-m8 45–51
miR-106b-5p 1.789 9.32E-11 8mer 822–829
Table 1. Predicted miRNA targets differentially expressed in the IPN during acute nicotine withdrawal. 
TargetScan Mouse 7.1 predicted conserved MREs within the 3′-UTRs of a subset of mRNAs differentially 
expressed in the IPN of NAWD mice compared to TA controls. miRNAs conserved in vertebrates and mammals 
that were inversely expressed (FDR < 0.01) and predicted to target these MREs are listed. Only mRNAs with a 
FC > 2 and an FDR < 0.01 were included in target prediction analysis. Seed type of the predicted MRE and its 
position within the 3′-UTR are listed.
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mRNA mRNA FC mRNA FDR miRNA miRNA FC miRNA FDR Seed Type Position in 3′-UTR
Arf5 4.543 1.01E-24 miR-29b-3p 0.650 4.95E-06 8mer 392–399
Pcolce2 4.447 9.69E-19
miR-340-5p 0.618 2.19E-10 7mer-A1 329–335
miR-146b-5p 0.721 1.68E-04 7mer-A1 3039–3045
Tom1l1 4.011 2.74E-21
miR-340-5p 0.618 2.19E-10 7mer-A1 397–403
miR-340-5p 0.618 2.19E-10 8mer 2622–2629
miR-181b-5p 0.763 2.71E-03 8mer 371–378
miR-142a-5p 0.765 8.25E-03 7mer-A1 2622–2628
miR-181c-5p 0.770 3.26E-03 8mer 371–378
Rasd1 3.629 3.25E-11
miR-377-3p 0.558 4.71E-04 7mer-m8 572–578
miR-30c-5p 0.710 2.01E-04 8mer 465-–472
miR-384-5p 0.735 3.14E-04 8mer 465–472
Pcna 3.195 6.07E-16 miR-137-3p 0.652 9.24E-08 8mer 420–427
Spns1 3.031 1.55E-11 miR-29b-3p 0.650 4.95E-06 8mer 266–273
Ppp2cb 3.022 5.91E-20
miR-183-5p 0.551 2.97E-06 8mer 152–159
miR-142a-5p 0.765 8.25E-03 7mer-A1 142–148
Steap3 2.857 2.10E-06 miR-377-3p 0.558 4.71E-04 7mer-A1 704–710
Dnajc9 2.787 7.78E-14 miR-132-3p 0.710 1.32E-04 7mer-m8 1040–1046
Rpa1 2.704 2.98E-15
miR-30c-5p 0.710 2.01E-04 7mer-m8 1195–1201
miR-384-5p 0.735 3.14E-04 7mer-m8 1195–1201
miR-361-5p 0.762 2.72E-03 7mer-m8 591–597
miR-361-5p 0.762 2.72E-03 7mer-A1 627–633
Net1 2.675 4.10E-07
miR-340-5p 0.618 2.19E-10 7mer-A1 31–37
miR-135a-5p 0.631 7.96E-09 8mer 831–838
miR-135b-5p 0.645 4.36E-05 8mer 831–838
Gpx4 2.617 1.68E-17 miR-374b-5p 0.549 2.62E-05 7mer-A1 833–839
Ogfod2 2.613 3.97E-11 miR-340-5p 0.618 2.19E-10 493-500 8mer
Sin3a 2.598 2.68E-09
miR-211-5p 0.492 7.97E-12 7mer-m8 870–876
miR-183-5p 0.551 2.97E-06 7mer-m8 644–650
miR-493-5p 0.699 3.98E-03 7mer-m8 724–730
miR-493-5p 0.699 3.98E-03 8mer 840–847
Eif5a 2.561 5.52E-19 miR-495-3p 0.472 8.00E-16 7mer-A1 589–595
Gosr2 2.511 5.84E-16 miR-493-5p 0.699 3.98E-03 8mer 1649–1656
Chst15 2.455 2.63E-07 miR-342-3p 0.704 8.42E-05 8mer 1364–1371
Tmem159 2.443 1.65E-04
miR-135a-5p 0.631 7.96E-09 7mer-m8 607–613
miR-135b-5p 0.645 4.36E-05 7mer-m8 607–613
Rab40b 2.414 3.16E-05 miR-211-5p 0.492 7.97E-12 8mer 336–343
Rabl6 2.413 2.15E-08
miR-30c-5p 0.710 2.01E-04 8mer 371–378
miR-384-5p 0.735 3.14E-04 8mer 371–378
Id3 2.400 5.82E-11 miR-340-5p 0.618 2.19E-10 7mer-A1 489–495
Htra2 2.381 6.59E-05 miR-410-3p 0.667 4.11E-07 7mer-A1 160–166
Kctd3 2.355 2.23E-08
miR-29b-3p 0.650 4.95E-06 7mer-A1 432–438
miR-30c-5p 0.710 2.01E-04 7mer-m8 411–417
miR-384-5p 0.735 3.14E-04 7mer-m8 411–417
Atg16l1 2.346 3.04E-12
let-7k 0.615 1.81E-04 7mer-A1 235–241
miR-410-3p 0.667 4.11E-07 8mer 1100–1107
miR-142a-5p 0.765 8.25E-03 7mer-m8 872–878
Srl 2.344 8.98E-04
miR-211-5p 0.492 7.97E-12 8mer 2918–2925
miR-136-5p 0.582 2.87E-08 8mer 818–825
miR-136-5p 0.582 2.87E-08 8mer 4468–4475
Marcksl1 2.271 1.11E-08
miR-23b-3p 0.740 1.75E-03 8mer 576–583
miR-23a-3p 0.755 3.09E-03 8mer 576–583
Ccdc32 2.241 2.68E-07 miR-377-3p 0.558 4.71E-04 7mer-m8 165–171
Prpf19 2.227 2.45E-17
miR-377-3p 0.558 4.71E-04 8mer 2354–2361
miR-421-3p 0.701 6.33E-03 8mer 2841–2848
miR-203-3p 0.732 7.63E-04 7mer-m8 120–126
Continued
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to physiological stimuli50. Interestingly, inhibition of ROCK in the mouse brain induces anxiety51. Our GO anal-
ysis revealed an enrichment of down-regulated genes related to cellular projection organization and neuron pro-
jection development in the IPN during nicotine withdrawal, possibly reflecting changes in neuron morphology 
regulated by the repression of Pfn2 expression.
mRNA mRNA FC mRNA FDR miRNA miRNA FC miRNA FDR Seed Type Position in 3′-UTR
Tbc1d8b 2.222 2.86E-03
miR-340-5p 0.618 2.19E-10 8mer 2336–2343
miR-142a-5p 0.765 8.25E-03 7mer-m8 1016–1022
miR-142a-5p 0.765 8.25E-03 7mer-A1 2336–2341
Kdelr1 2.222 7.47E-08
miR-340-5p 0.618 2.19E-10 7mer-A1 313–319
miR-335-5p 0.637 4.58E-06 7mer-A1 715–721
Gm2a 2.184 1.22E-07 miR-6395 0.682 5.46E-03 8mer 591–598
Zfp622 2.170 1.71E-11
miR-181b-5p 0.763 2.71E-03 8mer 410–417
miR-181c-5p 0.770 3.26E-03 8mer 410–417
Gap43 2.163 3.62E-03
miR-23b-3p 0.740 1.75E-03 7mer-m8 433–439
miR-23a-3p 0.755 3.09E-03 7mer-m8 433–439
Grasp 2.157 9.32E-04 miR-132-3p 0.710 1.32E-04 7mer-m8 668–674
Gpr182 2.134 4.61E-03
miR-30c-5p 0.710 2.01E-04 7mer-A1 2658–2664
miR-384-5p 0.735 3.14E-04 7mer-A1 2658–2664
Metap1 2.125 1.20E-06
miR-211-5p 0.492 7.97E-12 7mer-m8 1354–1360
miR-382-3p 0.528 3.46E-11 7mer-m8 1373–1379
miR-181b-5p 0.763 2.71E-03 7mer-m8 1334–1340
miR-142a-5p 0.765 8.25E-03 7mer-m8 1221–1227
miR-181c-5p 0.770 3.26E-03 7mer-m8 1334–1340
Chid1 2.123 5.05E-07 miR-142a-5p 0.765 8.25E-03 7mer-m8 2673–2679
Tmem184a 2.121 3.51E-03
miR-137-3p 0.652 9.24E-08 8mer 2889–2896
miR-410-3p 0.667 4.11E-07 7mer-A1 3706–3712
miR-493-5p 0.699 3.98E-03 7mer-m8 2883–2889
miR-487b-3p 0.702 4.08E-04 8mer 3684–3691
Htr2c 2.106 2.43E-10
miR-382-3p 0.528 3.46E-11 8mer 1230–1237
miR-137-3p 0.652 9.24E-08 8mer 2964–2971
miR-23b-3p 0.740 1.75E-03 8mer 1871–1878
miR-23a-3p 0.755 3.09E-03 8mer 1871–1878
Alpl 2.103 3.66E-06 miR-211-5p 0.492 7.97E-12 8mer 655–662
Ddah2 2.093 1.58E-08 miR-29b-3p 0.650 4.95E-06 7mer-m8 69–75
Zkscan4 2.087 1.94E-05 miR-29b-3p 0.650 4.95E-06 7mer-A1 390–396
Atg7 2.087 1.98E-05
miR-211-5p 0.492 7.97E-12 8mer 1454–1461
miR-382-3p 0.528 3.46E-11 7mer-m8 1438–1444
miR-142a-5p 0.765 8.25E-03 7mer-m8 879–885
Galnt18 2.083 1.04E-04 miR-340-5p 0.618 2.19E-10 7mer-A1 245–251
Thg1l 2.060 1.05E-03 miR-340-5p 0.618 2.19E-10 7mer-A1 280–286
Slc25a18 2.045 5.08E-05 let-7k 0.615 1.81E-04 8mer 106–113
Api5 2.023 3.22E-09 miR-203-3p 0.732 7.63E-04 8mer 1699–1706
Bcl2l1 2.020 8.98E-07
miR-495-3p 0.472 8.00E-16 7mer-A1 1219–1225
miR-377-3p 0.558 4.71E-04 7mer-m8 1242–1248
miR-377-3p 0.558 4.71E-04 8mer 1424–1431
let-7k 0.615 1.81E-04 8mer 947–954
miR-342 0.704 8.42E-05 7mer-m8 1243–1249
Cat 2.014 3.45E-06
miR-23b-3p 0.740 1.75E-03 8mer 793–800
miR-23a-3p 0.755 3.09E-03 8mer 793–800
Ccdc80 2.011 6.43E-03
miR-29b-3p 0.650 4.95E-06 8mer 213–220
miR-433-3p 0.673 1.45E-05 8mer 1243–1250
Table 2. Predicted miRNA targets differentially expressed in the MHb during acute nicotine withdrawal. 
TargetScan Mouse 7.1 predicted conserved MREs within the 3′-UTRs of a subset of mRNAs differentially 
expressed in the MHb of NAWD mice compared to TA controls. miRNAs conserved in vertebrates and 
mammals that were inversely expressed (FDR < 0.01) and predicted to target these MREs are listed. Only 
mRNAs with a FC > 2 and an FDR < 0.01 were included in target prediction analysis. Seed type of the predicted 
MRE and its position within the 3′-UTR are listed.
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In addition to various roles in mechanisms related to cytoskeletal dynamics underlying synaptic morphology, 
Pfn2 can also influence the composition of neurotransmitter receptors at post-synaptic surfaces42. For example, 
Pfn2 can decrease surface localization of excitatory kainate glutamate receptors through regulation of endocytosis 
and membrane trafficking52. Pfn2 also interacts with membrane scaffold proteins, such as gephyrin53, anchoring 
receptors to the cytoskeleton.
The synaptic roles of Pfn2 and its link to behaviors such as anxiety led us to hypothesize that down-regulation 
of Pfn2 during acute nicotine withdrawal contributes to the neural activation in the IPN during withdrawal, 
Figure 2. Knockdown of Pfn2 in the IPN is sufficient to increase anxiety. (A) Representative midbrain coronal 
section schematic and fluorescence microscopy images of WT mouse injected with either lenti-pGIPZ-Pfn2-
shRNA-tGFP (left image) or lenti-pGIPZ-Scramble-tGFP (right image) in the IPN. Nuclei were labeled with 
DAPI (blue). (B) Knockdown of Pfn2 expression was measured by RT-qPCR using RNA from laser-captured 
IPN tissue infected with lenti-pGIPZ-Pfn2-shRNA-tGFP compared to lenti-pGIPZ-scramble-tGFP control. 
mRNA expression was normalized to β-2-microglobulin. Statistical analysis using an unpaired, two-tailed t-test 
compared lenti-Pfn2 shRNA mice to lenti-scramble controls (t11 = 2.272, P < 0.05). (*)P < 0.05; n = 6–7. (C) 
Average time spent in the open arms and total number of arm entries in the elevated plus maze of mice injected 
with either lenti-Pfn2 shRNA (stippled bars) or lenti-scramble shRNA control (open bars) in the IPN. Statistical 
analysis used an unpaired two-tailed t-test to compare time spent in open arms (t33 = 3.583, P = 0.0011) and 
total number of arm entries (t33 = 0.7355, P = 0.4672) of lenti-Pfn2 shRNA mice to lenti-scramble controls. 
(**)P < 0.01 n = 16–19. Box plot edges are 25th and 75th percentile, central line is the median and whiskers are 
max and min. (D) Representative midbrain coronal section schematic and fluorescence microscopy image of 
WT mouse injected with lenti-pGIPZ-Pfn2-shRNA-tGFP in the VTA. Nuclei were labeled with DAPI (blue). 
(E) Average time spent in the open arms and average total number of arm entries in the elevated plus maze 
of mice injected with either lenti-Pfn2 shRNA (stippled bars) or lenti-scramble shRNA control (open bars) 
in the VTA. Unpaired, two-tailed t-test was used for statistical analysis of time spent in open arms (t16 = 1.09, 
P = 0.2918) and total arm entries (t16 = 0.4153, P = 0.6835). n = 9. Box plot edges are 25th and 75th percentile, 
central line is the median and whiskers are max and min.
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increasing anxiety-associated behaviors. Supporting this hypothesis, we show that knockdown of Pfn2 expression 
in the IPN of nicotine-naïve mice was sufficient to increase anxiety as measured by EPM, mimicking behaviors 
observed in WT mice during acute nicotine withdrawal. Effects on behavior are specific for anxiety, with no 
alterations in locomotor activity or object novelty preference. The effect of Pfn2 knockdown is also specific to 
the IPN, as knockdown within the neighboring VTA does not increase anxiety. Our results suggest a role for 
the down-regulation of Pfn2 in neuroadaptations of synapses induced by acute nicotine withdrawal in the IPN. 
Importantly, with respect to physiological relevance, Pfn2 is highly expressed in the IPN (expression data of all 
miRNAs and mRNAs are included in the GEO database associated with this article). Pfn2 ranks 180th in abun-
dance (mean = 801.258 transcripts per million) amongst all genes detected in the IPN of at least one control 
replicate putting it in the top 1% of genes detected in at least one replicate (22,181 genes total). It seems likely that 
a significant reduction in expression of such a highly expressed gene whose product interacts with the cytoskele-
ton and proteins that regulate synaptic exo- and endocytosis will substantially impact neuronal function. Future 
studies should focus on determining the effect of withdrawal-induced repression of Pfn2 on neural activity and 
synaptic morphology in the IPN.
Our study uncovered wide-spread changes in gene expression of the habenulo-interpeduncular circuit during 
acute nicotine withdrawal. The multitude of genes and their predicted regulation by miRNAs represent potential 
novel mechanisms underlying the neuroadaptations of nicotine dependence. Hence, this dataset is a valuable 
resource, the use of which may lead to the identification of novel substrates for the design of innovative smoking 
cessation aids and the treatment of withdrawal symptoms, including anxiety. However, it is important to point out 
that, in addition to miRNA regulation of target genes, it is possible that the targets themselves regulate miRNA 
levels by regulating miRNA degradation19. This is particularly relevant to the nervous system where it has been 
shown that target RNA-directed miRNA degradation (TDMD) activity is substantially higher in primary neu-
rons versus non-neuronal cells and established cell lines54. Thus, our dataset may also prove useful for decipher-
ing TDMD pathways during withdrawal. However, there are limitations to our dataset that must be considered 
when analyzing miRNA/mRNA relationships following nicotine withdrawal. For example, some of the miRNAs 
identified using the mouse brain samples are not conserved in humans, raising obvious questions regarding their 
potential roles in the human condition. Further, while there are a plethora of miRNA/mRNA pairs conserved in 
all mammals, there are specific miRNA/mRNA pairs that are primate-specific38, which would obviously not be 
detected in our study utilizing mouse brain samples.
It is also of interest to utilize a similar sequencing strategy using other abused drugs (e.g., opioids) to deter-
mine whether a similar pattern of miRNA/mRNA regulation occurs in the habenulo-interpeduncular circuit, as it 
is likely that this circuit is involved in the withdrawal response to other drugs in addition to nicotine. Such a result 
would inform the rational development of therapeutic interventions.
Materials and Methods
Animals and drug treatment. All experiments were conducted in accordance with the guidelines for care 
and use of laboratory animals provided by the National Research Council as well as with an approved animal pro-
tocol from the Institutional Animal Care and Use Committee of the University of Massachusetts Medical School 
(UMMS). Wild-type (WT) male C57BL/6 J (Jackson) were group-housed and were kept on a 12-h light/dark cycle 
(lights ON 7 A.M.) with food and water provided ad libitum. Mice aged 6 weeks were treated with nicotine tartrate 
(200 μg/ml nicotine base) or equivalent tartaric acid in their drinking water with saccharine (3 g/L) to increase 
palatability. After 6 weeks, mice in spontaneous withdrawal groups had nicotine bottles replaced with tartaric 
acid solution. After a 48-hour (Fig. 1A) or 4-week withdrawal period, mice were tested in behavioral assays or 
sacrificed for tissue collection.
tissue collection and RnA isolation. Fresh frozen brains were coronally sliced (~1 mm) and regions 
were dissected using a circular tissue punch (0.75–1 mm diameter). Bregma ranges for each region were as fol-
lows: NAc: 1.8–0.8 mm; VTA: (−3.1) – (−3.9) mm; IPN: (−3.2) – (−3.9) mm. Punches were expelled in lysis 
buffer (miRVana miRNA isolation kit, Ambion). Punches from 4 or 2 brains were combined in each sample for 
sequencing and RT-qPCR experiments, respectively. Unless otherwise stated, total RNA was isolated using the 
miRVana kit according to manufacturer’s instructions. RNA concentration and A260/280 were assessed using a 
NanoDrop2000 (ThermoFisher).
Small RnA library synthesis. Total RNA (approximately 2–9 μg, A260/280 >1.8) was separated on a 15% 
polyacrylamide, 7 M urea, 1X TBE gel. Small RNA (18–30 nucleotides) was excised and eluted from the gel. 
Libraries were synthesized using a modified protocol for Illumina TruSeq Small RNA Cloning (April 2014, www.
zamorlab.umassmed.edu/protocols/). Briefly, small RNAs were ligated to 3′- and 5′-adapters and cDNA was 
reverse transcribed by AMV Reverse Transcriptase (NEB). The cDNA libraries were amplified by Accuprime Pfx 
DNA Polymerase (Invitrogen) for 18 PCR cycles using a common primer and a primer containing a 6-nucleotide 
barcoding index. The libraries were gel-purified on a 2.5% Low-Range Ultra Agarose (BioRad) 1X TBE gel 
and eluted using a QIAquick Gel Extraction kit (Qiagen). Library sizes were assessed by Fragment Analyzer 
(Advanced Analytical, AATI). Library concentrations were determined using KAPA Library Quantification Kits 
(KAPA Biosystems).
Adapter sequences. 3′-Adapter: 5′-rApp/nnntggaattctcgggtgccaagg/ddC/-3′
5′-Adapter: 5′-guucagaguucuacaguccgacgauc-3′
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Primers. RT primer: 5′-ccttggcacccgagaattcca-3′
PCR forward primer: 5′-aatgatacggcgaccaccgagatctacacgttcagagttctacagtccga-3′
PCR Index Primers (Barcode):
Index Primer 1: 5′-caagcagaagacggcatacgagatcgtgatgtgactggagttccttggcacccgagaattcca-3′
Index Primer 2: 5′-caagcagaagacggcatacgagatacatcggtgactggagttccttggcacccgagaattcca-3′
Index Primer 3: 5′-caagcagaagacggcatacgagatgcctaagtgactggagttccttggcacccgagaattcca-3′
Index Primer 4: 5′-caagcagaagacggcatacgagattggtcagtgactggagttccttggcacccgagaattcca-3′
Index Primer 5: 5′-caagcagaagacggcatacgagatcactgtgtgactggagttccttggcacccgagaattcca-3′
Index Primer 6: 5′-caagcagaagacggcatacgagatattggcgtgactggagttccttggcacccgagaattcca-3′
Index Primer 7: 5′-caagcagaagacggcatacgagatgatctggtgactggagttccttggcacccgagaattcca-3′
Index Primer 8: 5′-caagcagaagacggcatacgagattcaagtgtgactggagttccttggcacccgagaattcca-3′
Index Primer 9: 5′-caagcagaagacggcatacgagatctgatcgtgactggagttccttggcacccgagaattcca-3′
Index Primer 10: 5′-caagcagaagacggcatacgagataagctagtgactggagttccttggcacccgagaattcca-3′
Index Primer 11: 5′-caagcagaagacggcatacgagatgtagccgtgactggagttccttggcacccgagaattcca-3′
Index Primer 12: 5′-caagcagaagacggcatacgagattacaaggtgactggagttccttggcacccgagaattcca-3′
Index Primer 14: 5′-caagcagaagacggcatacgagatggaactgtgactggagttccttggcacccgagaattcca-3′
Index Primer 15: 5′-caagcagaagacggcatacgagattgacatgtgactggagttccttggcacccgagaattcca-3′
Index Primer 16: 5′-caagcagaagacggcatacgagatggacgggtgactggagttccttggcacccgagaattcca-3′
Small RnA sequencing and analysis. Small RNA libraries were pooled and subjected to single-end 
(75 cycles) sequencing using a NextSeq. 500 (Illumina) in the RNA Therapeutics Institute at UMMS. Following 
sequencing, the 3′-adapter sequence was removed using Cutadapt (version 1.11) with ‘–overlap’ option 7 bp. 
Reads between 15–27 nucleotides long (Fig. S1) were mapped to the UCSC mouse reference genome (mm10) 
using Bowtie (version 1.1.2) allowing for no mismatches. miRNA reads ±5 nucleotides from the mature, anno-
tated 5′-start position were counted. Reads mapping to multiple locations on a single mature miRNA were 
recorded as a single count and reads mapped to multiple mature miRNAs were apportioned by the number of the 
aligned mature miRNAs. Prior to DESeq. 2, read counts were normalized using RUV-Seq55, removing 3–4 factors 
of variance. In each condition, miRNAs with 0 reads per million (RPM) in more than half the samples were omit-
ted from the analysis. Samples with greater than 1 million mappable reads were used in differential expression 
(DE) analysis by DESeq. 2 (FDR < 0.01)56.
mRnA library synthesis. RNA >30 nucleotides long was eluted from the same denaturing gel as the small 
RNA. Libraries were synthesized using the TruSeq Stranded mRNA Library Prep kit (Illumina) according to 
manufacturer’s instructions. Libraries were gel-purified, assessed by Fragment Analyzer and their concentrations 
were quantified as described for the small RNA libraries.
mRnA sequencing and analysis. mRNA libraries were subjected to paired-end (76 cycles x 2) sequenc-
ing. Reads were mapped to the UCSC mouse reference genome (mm10) using STAR (version 2.5.3a). Following 
sequencing, mapped reads were quantified with RSEM (version 1.3.0) and RNA-seq libraries with >30 million 
mappable reads were used in DE analysis by DESeq. 2 (version 1.14.1; FDR < 0.01 and fold change >2). Prior to 
the DE analysis, read counts were normalized using RUV-Seq (version 1.8.0)55 to remove unwanted variables 
including batch effects. Genome Ontology (GO) term enrichment for biological processes, molecular function, 
and cellular component was performed on DE mRNAs using GOseq (version 1.28.0)57. REVIGO was used to 
reduce GO terms by combining closely related terms58. To provide a well-balanced representation of reduced GO 
terms, a simRel cutoff of 0.4 was used59. Raw and processed RNA-Seq data are available at the Gene Expression 
Omnibus (GEO) of the National Center for Biotechnology Information (NCBI) of the National Institutes of 
Health, accession # GSE117069. Reviewers, please see ‘Data Availability’ section for access token.
Quantitative reverse transcription-pcR (Rt-qpcR). RT-qPCR for miRNAs and mRNAs was per-
formed as previously described30 using TaqMan assays (ThermoFisher) for miR-106b-5p (Assay ID 000442), 
Pfn2 (Assay ID Mm01289572_m1), and Pfn1 (Assay ID Mm00726691_s1). Relative miRNA/gene expression was 
determined using the 2−ΔΔCt method60. miRNA and mRNA expression were normalized to snoRNA202 (Assay 
ID 001232) and β-glucuronidase (Assay ID Mm01197698_m1), respectively, unless otherwise noted.
target prediction analysis. TargetScan Mouse 7.1 (http://www.targetscan.org/mmu_71/) was used to 
identify DE miRNAs that are predicted to target conserved MREs within the 3′-UTR of inversely expressed 
mRNAs. Analysis was limited to miRNAs conserved in vertebrates and mammals.
In Vitro Knockdown of Pfn2 with Lenti-pGIPZ-Pfn2-shRNA-tGFP. The mouse septal cholinergic 
cell line SN1761 was used to test distinct shRNAs for their abilities to knock down expression of Pfn2. SN17 
cells were grown in Dulbecco’s Modified Eagle’s Medium (1X DMEM, Corning) supplemented with 10% fetal 
bovine serum and 100 U/ml penicillin/streptomycin. The cells were infected with three lots of commercially 
available lentiviral particles expressing one of three distinct shRNAs directed against Pfn2 or a scramble shRNA 
control (Lenti-pGIPZ-shRNA, Dharmacon). The shRNA source clones targeted the following sequences: 
V3LMM_494366 5′-TTTCCTACAATCATATCTA-3′, V3LMM_494367 5′-TATCCACGTAGCTCTGCCA-3′, 
V3LMM_494369 5′-CTGATCACAGAACACTTCT-3′. SN17 cells (passage 5) were seeded at a density of 
2.5 × 104 cells per well in a 24-well plate and incubated overnight. Cells were transduced with lentivirus 
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(multiplicity of infection 0.4) in technical duplicates using 8 μg/ml polybrene in a total of 250 μl in each well. After 
5 hours, an additional 1 ml of complete growth medium was added to each well. Approximately 48 hours after 
transduction, medium was aspirated and replaced with 0.5 ml of complete growth medium containing 2.5 μg/ml 
puromycin to select for cells successfully transduced with lentivirus. Puromycin selection was performed for a 
total of 5 days, changing medium every other day. On day 5, cells were harvested and total RNA was isolated using 
the RNAqueous Total RNA Isolation Kit (ThermoFisher AM1912), eluting in 60 μl. RNA (125 ng) was reverse 
transcribed using M-MLV Reverse Transcriptase (ThermoFisher Cat No. 28025013) according to manufacturer’s 
instructions. Relative expression of Pfn2 was measured by RT-qPCR as described above.
shRnA-mediated inhibition of Pfn2. To inhibit Pfn2 expression in vivo, we employed lentiviral 
delivery of shRNA targeting Pfn2 (sense sequence 5′-AGAAGTGTTCTGTGATCAG-3′) to the IPN or VTA. 
Lenti-pGIPZ-Pfn2-shRNA-tGFP (2.37 × 108 TU/ml, V3LMM_494369, Dharmacon) or a control virus expressing 
a non-silencing shRNA (lenti-pGIPZ-scramble-tGFP, 9.06 × 108 TU/ml, RHS4348, Dharmacon) were injected 
into IPN or VTA and expressed for 4 weeks prior to all experiments. Stereotaxic injections were performed under 
aseptic conditions using mice aged 6 weeks as described by Molas et al.34. Virus was injected in the IPN or VTA 
(unilateral) at coordinates measured from Bregma (in mm, anterioposterior, mediolateral, dorsoventral at 0°): 
IPN (−3.47, ±0, −4.77), VTA (−3.45, ±0.5, −4.2) using a 26 s gauge 10-μl syringe (701RN, Hamilton) to deliver 
300 nl of virus at a controlled rate of 60 nl/min.
Fresh frozen brains were cryosectioned (12-μm), fixed in ice-cold acetone, and dehydrated in ethanol (70%, 
90%, 100%) and xylenes. Areas expressing tGFP were isolated by laser capture microdissection (LCM; Arcturus). 
RNA was isolated using RNAqueous-Micro Total RNA Isolation Kit (Ambion) for RT-qPCR.
Behavioral assays. All behavioral testing was performed during the light phase (8:00 A.M. to 5:00 P.M.) in 
dim white light after habituation to the testing room (≥30 min). On the first test day, mice underwent the marble 
burying test followed by the elevated plus maze (EPM) as described by Zhao-Shea et al.16. Approximately 48 hours 
later, mice underwent object novelty preference testing. Testing was performed in two cohorts of virus-injected 
mice, with balanced treatment groups by experimenters blind to virus injection. Lenti-virus expression was con-
firmed by fluorescence microscopy of tGFP. Mice with no virus expression in the brain region of interest were 
excluded from analysis.
Marble burying. For 2 days prior to testing, mice were habituated to individual standard mouse cages, filled 
5–6 cm with bedding material, for approximately 1 hour per day. On the test day, 15 sterilized 1.5-cm diameter 
glass marbles were placed in the cages, equally spaced in a 3 × 5 grid arrangement. Mice were placed in the test 
cage for 30 min. then returned to their home cage. The number of marbles buried at least 75% with bedding was 
counted.
Object novelty preference test. A T-shaped maze (three arms, each 9 × 30 × 20 cm, connected through a 9 × 9 cm 
central zone) made of white Plexiglas was used to examine interest in familiar and novel inanimate objects under 
dim red light conditions. First, the mouse was habituated to the apparatus for 5 min and removed. Two identical 
plastic objects were placed in the ends of the T-maze, one in each end. The mouse was immediately placed back 
into the maze for 5 min and allowed to investigate the two identical novel objects (N1). The mouse was removed 
and one object was replaced by a novel object in the same location as the previous object (counter-balanced). The 
mouse was immediately placed in the T-maze and allowed to investigate the familiar (F1) and novel (N2) objects. 
All sessions were video recorded from above (HDR-CX4440 camera, Sony) and mouse behavior was tracked 
automatically using EthoVision XT 11.5 (Noldus Apparatus). A blind experimenter manually scored the times 
the mouse explored the familiar and novel objects. Exploration was defined as sniffing with the nose directed at 
the object from a distance of less than 2 cm. Simply sitting or resting next to the object was not counted as explo-
ration. The novel object preference ratio was calculated as: (total novel object investigation – total investigation)/
(total investigation) over the third 5-min session. The apparatus and objects were cleaned with Micro-90 solution 
(International Products Corporation) to eliminate olfactory traces after each session.
Data availability
Raw and processed RNA-Seq data are available at the Gene Expression Omnibus (GEO) of the National Center 
for Biotechnology Information (NCBI) of the National Institutes of Health, accession # GSE117069.
Received: 27 May 2019; Accepted: 8 January 2020;
Published: xx xx xxxx
References
 1. Peacock, A. et al. Global statistics on alcohol, tobacco and illicit drug use: 2017 status report. Addiction, https://doi.org/10.1111/
add.14234 (2018).
 2. Organization, W. H. WHO Report on the Global Tobacco Epidemic, 2011. (2011).
 3. Kotz, D., Brown, J. & West, R. ‘Real-world’ effectiveness of smoking cessation treatments: a population study. Addiction 109, 
491–499, https://doi.org/10.1111/add.12429 (2014).
 4. Jorenby, D. E. et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-
release bupropion for smoking cessation: a randomized controlled trial. JAMA 296, 56–63, https://doi.org/10.1001/jama.296.1.56 
(2006).
 5. Koegelenberg, C. F. et al. Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking 
cessation: a randomized clinical trial. JAMA 312, 155–161, https://doi.org/10.1001/jama.2014.7195 (2014).
13Scientific RepoRtS |          (2020) 10:813  | https://doi.org/10.1038/s41598-020-57907-w
www.nature.com/scientificreportswww.nature.com/scientificreports/
 6. Cinciripini, P. M. et al. Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on 
prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal. JAMA 
Psychiatry 70, 522–533, https://doi.org/10.1001/jamapsychiatry.2013.678 (2013).
 7. Albuquerque, E. X., Pereira, E. F., Alkondon, M. & Rogers, S. W. Mammalian nicotinic acetylcholine receptors: from structure to 
function. Physiol Rev 89, 73–120, https://doi.org/10.1152/physrev.00015.2008 (2009).
 8. Picciotto, M. R. & Mineur, Y. S. Molecules and circuits involved in nicotine addiction: The many faces of smoking. 
Neuropharmacology 76(Pt B), 545–553, https://doi.org/10.1016/j.neuropharm.2013.04.028 (2014).
 9. Dani, J. A. & De Biasi, M. Mesolimbic dopamine and habenulo-interpeduncular pathways in nicotine withdrawal. Cold Spring Harb 
Perspect Med 3, 1–13, https://doi.org/10.1101/cshperspect.a012138 (2013).
 10. Molas, S., DeGroot, S. R., Zhao-Shea, R. & Tapper, A. R. Anxiety and Nicotine Dependence: Emerging Role of the Habenulo-
Interpeduncular Axis. Trends Pharmacol Sci 38, 169–180, https://doi.org/10.1016/j.tips.2016.11.001 (2017).
 11. Hughes, J. R. Effects of abstinence from tobacco: valid symptoms and time course. Nicotine Tob Res 9, 315–327, https://doi.
org/10.1080/14622200701188919 (2007).
 12. Jackson, K. J., Muldoon, P. P., De Biasi, M. & Damaj, M. I. New mechanisms and perspectives in nicotine withdrawal. 
Neuropharmacology 96, 223–234, https://doi.org/10.1016/j.neuropharm.2014.11.009 (2015).
 13. Koob, G. F. & Le Moal, M. Review. Neurobiological mechanisms for opponent motivational processes in addiction. Philos Trans R 
Soc Lond B Biol Sci 363, 3113–3123, https://doi.org/10.1098/rstb.2008.0094 (2008).
 14. Allen, S. S., Bade, T., Hatsukami, D. & Center, B. Craving, withdrawal, and smoking urges on days immediately prior to smoking 
relapse. Nicotine Tob Res 10, 35–45, https://doi.org/10.1080/14622200701705076 (2008).
 15. Zhao-Shea, R., Liu, L., Pang, X., Gardner, P. D. & Tapper, A. R. Activation of GABAergic neurons in the interpeduncular nucleus 
triggers physical nicotine withdrawal symptoms. Curr Biol 23, 2327–2335, https://doi.org/10.1016/j.cub.2013.09.041 (2013).
 16. Zhao-Shea, R. et al. Increased CRF signalling in a ventral tegmental area-interpeduncular nucleus-medial habenula circuit induces 
anxiety during nicotine withdrawal. Nat Commun 6, 6770, https://doi.org/10.1038/ncomms7770 (2015).
 17. Madsen, H. B., Brown, R. M. & Lawrence, A. J. Neuroplasticity in addiction: cellular and transcriptional perspectives. Front Mol 
Neurosci 5, 99, https://doi.org/10.3389/fnmol.2012.00099 (2012).
 18. Robison, A. J. & Nestler, E. J. Transcriptional and epigenetic mechanisms of addiction. Nat Rev Neurosci 12, 623–637, https://doi.
org/10.1038/nrn3111 (2011).
 19. Bartel, D. P. Metazoan MicroRNAs. Cell 173, 20–51 (2018).
 20. Lewis, B. P., Shih, I. H., Jones-Rhoades, M. W., Bartel, D. P. & Burge, C. B. Prediction of mammalian microRNA targets. Cell 115, 
787–798 (2003).
 21. Bartel, D. P. MicroRNAs: target recognition and regulatory functions. Cell 136, 215–233, https://doi.org/10.1016/j.cell.2009.01.002 
(2009).
 22. Shan, H. et al. Downregulation of miR-133 and miR-590 contributes to nicotine-induced atrial remodelling in canines. Cardiovasc 
Res 83, 465–472, https://doi.org/10.1093/cvr/cvp130 (2009).
 23. Zhang, Y., Pan, T., Zhong, X. & Cheng, C. Nicotine upregulates microRNA-21 and promotes TGF-beta-dependent epithelial-
mesenchymal transition of esophageal cancer cells. Tumour Biol 35, 7063–7072, https://doi.org/10.1007/s13277-014-1968-z (2014).
 24. Izzotti, A. et al. Dose-responsiveness and persistence of microRNA expression alterations induced by cigarette smoke in mouse lung. 
Mutat Res 717, 9–16, https://doi.org/10.1016/j.mrfmmm.2010.12.008 (2011).
 25. Izzotti, A. et al. Downregulation of microRNA expression in the lungs of rats exposed to cigarette smoke. FASEB J 23, 806–812, 
https://doi.org/10.1096/fj.08-121384 (2009).
 26. Takahashi, K. et al. Cigarette smoking substantially alters plasma microRNA profiles in healthy subjects. Toxicol Appl Pharmacol 
272, 154–160, https://doi.org/10.1016/j.taap.2013.05.018 (2013).
 27. Im, H. I. & Kenny, P. J. MicroRNAs in neuronal function and dysfunction. Trends Neurosci 35, 325–334, https://doi.org/10.1016/j.
tins.2012.01.004 (2012).
 28. Hollander, J. A. et al. Striatal microRNA controls cocaine intake through CREB signalling. Nature 466, 197–202, https://doi.
org/10.1038/nature09202 (2010).
 29. Lippi, G. et al. Targeting of the Arpc3 actin nucleation factor by miR-29a/b regulates dendritic spine morphology. J Cell Biol 194, 
889–904, https://doi.org/10.1083/jcb.201103006 (2011).
 30. Hogan, E. M. et al. miRNAome analysis of the mammalian neuronal nicotinic acetylcholine receptor gene family. RNA 20, 
1890–1899, https://doi.org/10.1261/rna.034066.112 (2014).
 31. Lee, S., Woo, J., Kim, Y. S. & Im, H. I. Integrated miRNA-mRNA analysis in the habenula nuclei of mice intravenously self-
administering nicotine. Sci Rep 5, 12909, https://doi.org/10.1038/srep12909 (2015).
 32. Witke, W., Sutherland, J. D., Sharpe, A., Arai, M. & Kwiatkowski, D. J. Profilin I is essential for cell survival and cell division in early 
mouse development. Proc Natl Acad Sci USA 98, 3832–3836, https://doi.org/10.1073/pnas.051515498 (2001).
 33. Pilo Boyl, P. et al. Profilin2 contributes to synaptic vesicle exocytosis, neuronal excitability, and novelty-seeking behavior. EMBO J 
26, 2991–3002, https://doi.org/10.1038/sj.emboj.7601737 (2007).
 34. Molas, S. et al. A circuit-based mechanism underlying familiarity signaling and the preference for novelty. Nat Neurosci 20, 
1260–1268, https://doi.org/10.1038/nn.4607 (2017).
 35. Devine, M. J. & Kittler, J. T. Mitochondria at the neuronal presynapse in health and disease. Nat Rev Neurosci 19, 63–80, https://doi.
org/10.1038/nrn.2017.170 (2018).
 36. Harris, J. J., Jolivet, R. & Attwell, D. Synaptic energy use and supply. Neuron 75, 762–777, https://doi.org/10.1016/j.neuron.2012.08.019 
(2012).
 37. Magistretti, P. J. & Allaman, I. A cellular perspective on brain energy metabolism and functional imaging. Neuron 86, 883–901, 
https://doi.org/10.1016/j.neuron.2015.03.035 (2015).
 38. Soreq, H. Checks and balances on cholinergic signaling in brain and body function. Trends Neurosci 38, 448–458, https://doi.
org/10.1016/j.tins.2015.05.007 (2015).
 39. Shaked, I. et al. MicroRNA-132 potentiates cholinergic anti-inflammatory signaling by targeting acetylcholinesterase. Immunity 31, 
965–973, https://doi.org/10.1016/j.immuni.2009.09.019 (2009).
 40. Mishra, N. et al. Antisense miR-132 blockade via the AChE-R splice variant mitigates cortical inflammation. Sci Rep 7, 42755, 
https://doi.org/10.1038/srep42755 (2017).
 41. Bekenstein, U. et al. Dynamic changes in murine forebrain miR-211 expression associate with cholinergic imbalances and 
epileptiform activity. Proc Natl Acad Sci USA 114, E4996–E5005, https://doi.org/10.1073/pnas.1701201114 (2017).
 42. Witke, W. The role of profilin complexes in cell motility and other cellular processes. Trends Cell Biol 14, 461–469, https://doi.
org/10.1016/j.tcb.2004.07.003 (2004).
 43. Honore, B., Madsen, P., Andersen, A. H. & Leffers, H. Cloning and expression of a novel human profilin variant, profilin II. FEBS 
Lett 330, 151–155 (1993).
 44. Tariq, N., Basharat, Z., Butt, S. & Baig, D. N. Distribution analysis of profilin isoforms at transcript resolution with mRNA-seq and 
secondary structure in various organs of Rattus norvegicus. Gene 589, 49–55, https://doi.org/10.1016/j.gene.2016.05.023 (2016).
 45. Gareus, R., Di Nardo, A., Rybin, V. & Witke, W. Mouse profilin 2 regulates endocytosis and competes with SH3 ligand binding to 
dynamin 1. J Biol Chem 281, 2803–2811, https://doi.org/10.1074/jbc.M503528200 (2006).
1 4Scientific RepoRtS |          (2020) 10:813  | https://doi.org/10.1038/s41598-020-57907-w
www.nature.com/scientificreportswww.nature.com/scientificreports/
 46. Witke, W. et al. In mouse brain profilin I and profilin II associate with regulators of the endocytic pathway and actin assembly. 
EMBO J 17, 967–976, https://doi.org/10.1093/emboj/17.4.967 (1998).
 47. Ackermann, M. & Matus, A. Activity-induced targeting of profilin and stabilization of dendritic spine morphology. Nat Neurosci 6, 
1194–1200, https://doi.org/10.1038/nn1135 (2003).
 48. Lamprecht, R., Farb, C. R., Rodrigues, S. M. & LeDoux, J. E. Fear conditioning drives profilin into amygdala dendritic spines. Nat 
Neurosci 9, 481–483, https://doi.org/10.1038/nn1672 (2006).
 49. Michaelsen, K. et al. Fine-tuning of neuronal architecture requires two profilin isoforms. Proc Natl Acad Sci USA 107, 15780–15785, 
https://doi.org/10.1073/pnas.1004406107 (2010).
 50. Da Silva, J. S. et al. RhoA/ROCK regulation of neuritogenesis via profilin IIa-mediated control of actin stability. J Cell Biol 162, 
1267–1279, https://doi.org/10.1083/jcb.200304021 (2003).
 51. Saitoh, A. et al. ROCK inhibition produces anxiety-related behaviors in mice. Psychopharmacology (Berl) 188, 1–11, https://doi.
org/10.1007/s00213-006-0466-4 (2006).
 52. Mondin, M., Carta, M., Normand, E., Mulle, C. & Coussen, F. Profilin II regulates the exocytosis of kainate glutamate receptors. J 
Biol Chem 285, 40060–40071, https://doi.org/10.1074/jbc.M110.140442 (2010).
 53. Mammoto, A. et al. Interactions of drebrin and gephyrin with profilin. Biochem Biophys Res Commun 243, 86–89, https://doi.
org/10.1006/bbrc.1997.8068 (1998).
 54. de la Mata, M. et al. Potent degradation of neuronal miRNAs induced by highly complementary targets. EMBO Rep 16, 500–511, 
https://doi.org/10.15252/embr.201540078 (2015).
 55. Risso, D., Ngai, J., Speed, T. P. & Dudoit, S. Normalization of RNA-seq data using factor analysis of control genes or samples. Nat 
Biotechnol 32, 896–902, https://doi.org/10.1038/nbt.2931 (2014).
 56. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome 
Biol 15, 550, https://doi.org/10.1186/s13059-014-0550-8 (2014).
 57. Young, M. D., Wakefield, M. J., Smyth, G. K. & Oshlack, A. Gene ontology analysis for RNA-seq: accounting for selection bias. 
Genome Biol 11, R14, https://doi.org/10.1186/gb-2010-11-2-r14 (2010).
 58. Supek, F., Bosnjak, M., Skunca, N. & Smuc, T. REVIGO summarizes and visualizes long lists of gene ontology terms. PLoS One 6, 
e21800, https://doi.org/10.1371/journal.pone.0021800 (2011).
 59. Schlicker, A., Domingues, F. S., Rahnenfuhrer, J. & Lengauer, T. A new measure for functional similarity of gene products based on 
Gene Ontology. BMC Bioinformatics 7, 302, https://doi.org/10.1186/1471-2105-7-302 (2006).
 60. Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta 
C(T)) Method. Methods 25, 402–408, https://doi.org/10.1006/meth.2001.1262 (2001).
 61. Hammond, D. N., Lee, H. J., Tonsgard, J. H. & Wainer, B. H. Development and characterization of clonal cell lines derived from 
septal cholinergic neurons. Brain Res 512, 190–200 (1990).
Acknowledgements
We sincerely thank Drs. Phil Zamore and Jennifer Broderick for their help with library generation and Dr. Alper 
Kucukural for help with data analysis and uploading. This work was supported by award numbers F30DA036312 
(APC), U24HG009446 (ZW), R21DA033543 (PDG), and R21DA031952 (PDG and ART). The content is solely 
the responsibility of the authors and does not necessarily represent the official views of the National Institute for 
Drug Abuse or the National Institutes of Health.
Author contributions
A.P.C., J.T., R.Z.-S., S.M., A.R.T., Z.W. and P.D.G. designed the experiments. A.P.C., J.T., R.Z.-S., C.B.S. and S.M. 
performed the experiments. A.P.C., J.T., R.Z.-S., C.B.S., S.M., A.R.T., Z.W. and P.D.G. analyzed the data. A.P.C. 
and P.D.G. wrote the manuscript. All authors reviewed the manuscript.
competing interests
The authors declare no competing interests.
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-57907-w.
Correspondence and requests for materials should be addressed to P.D.G.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2020
